Why are tumour blood vessels abnormal and why is it important to know?
Open accessThe DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
Tumour blood vessels differ from their normal counterparts for reasons that have received little attention. We report here that they are of at least six distinct types, we describe how each forms, and, looking forward, encourage the targeting of tumour vessel subsets that have lost their vascular endothelial growth factor-A (VEGF-A) dependency and so are likely unresponsive to anti-VEGF-A therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Although many in vitro microvessel models have been developed, none of them can actually reproduce the architecture of capillaries seen in a tumor [217,218].”
From Microfluidic modelling of the tumor microenvironment for anti-cancer drug development (2019) · cites this paper as [217]
Experimental — accuracy not yet measuredIn the citing paper
“The vasculature of tumors is very different from the blood vessels that supply healthy tissues, especially in terms of heterogeneity, permeability, multidirectional blood flow, and unordered distribution throughout the tumor160.”
From Tumor-on-a-chip: from bioinspired design to biomedical application (2021) · cites this paper as [160]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tumor angiogenesis: therapeutic implications
Sherwood, L. M., Parris, E. E., & Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197111182852108 · Cited by 10,187 · cited 1×
“Furthermore, recent successes with agents that block VEGF-A or its receptors have supported Folkman’s (1971) thesis that anti-angiogenesis can be a useful supplement to traditional tumour therapy.”
BackgroundTumors: Wounds That Do Not Heal
Flier, J. S., Underhill, L. H., & Dvorak, H. F. (1986) · New England Journal of Medicine · doi:10.1056/nejm198612253152606 · Cited by 4,391 · cited 1×
“As was noted more than 20 years ago, tumour angiogenesis shares many analogies with wound healing (Dvorak, 1986).”
BackgroundSelf-citationTransplacental Carcinogenesis by Stilbestrol
Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197108122850711 · Cited by 2,640
Dll4 signalling through Notch1 regulates formation of tip cells during angiogenesis
Hellström, M., Phng, L.-K., Hofmann, J. J., Wallgard, E., Coultas, L., Lindblom, P., Alva, J., Nilsson, A.-K., Karlsson, L., Gaiano, N., et al. (2007) · Nature · doi:10.1038/nature05571 · Cited by 1,775 · cited 1×
“…of endothelial cells: non-dividing ‘tip’ cells at the leading edge that extend filopodia and sprouts in response to VEGF-A gradients and ‘stalk’ cells that follow behind, divide and exhibit reduced filopodia and sprouting because of signalling through the Notch/delta 4 axis (Hellstrom et al, 2007).”
BackgroundBergers, G., Song, S., Meyer-Morse, N., Bergsland, E., & Hanahan, D. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17929 · Cited by 1,370 · cited 1×
“…that anti-VEGF/VEGFR approaches have effectively treated mouse tumours at early stages of their development, but have proved to be less successful in treating established mouse tumours that contain large numbers of more mature, smooth muscle-cell-coated blood vessels (Bergers et al, 2003).”
BackgroundBergers, G., Song, S., Meyer-Morse, N., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200317929 · Cited by 1,192
Lessons from phase III clinical trials on anti-VEGF therapy for cancer
Jain, R. K., Duda, D. G., Clark, J. W., & Loeffler, J. S. (2006) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0403 · Cited by 1,039 · cited 2×
“Agents that neutralise VEGF (e.g., Avastin, VEGF-TRAP) or its receptors have provided proof of principle that anti-angiogenesis can be a useful adjunct to tumour therapy (Jain et al, 2006).”
BackgroundRuhrberg, C., Gerhardt, H., Golding, M., Watson, R., Ioannidou, S., Fujisawa, H., Betsholtz, C., & Shima, D. T. (2002) · Genes & Development · doi:10.1101/gad.242002 · Cited by 914 · cited 2×
“Mice engineered to express only VEGF-A120 develop to term but generate a capillary network with larger-sized vessels and fewer branch points (Ruhrberg et al, 2002).”
BackgroundLee, S., Jilani, S. M., Nikolova, G. V., Carpizo, D., & Iruela-Arispe, M. L. (2005) · The Journal of Cell Biology · doi:10.1083/jcb.200409115 · Cited by 703 · cited 2×
“Similar large, MV-like vessels can be generated by still smaller VEGF-As that result from matrix metalloprotease cleavage (Lee et al, 2005).”
BackgroundVasculogenic Mimicry and Tumor Angiogenesis
Folberg, R., Hendrix, M. J. C., & Maniotis, A. J. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64739-6 · Cited by 684 · cited 1×
“…and DV result, respectively, from arteriogenesis and venogenesis. aIn addition, red blood-cell-filled spaces lined by tumour cells rather than by vascular endothelium have been described in some tumours, particularly ocular melanomas, and are referred to as ‘vascular mimicry’ (Folberg et al, 2000).”
BackgroundVascular permeability, vascular hyperpermeability and angiogenesis
Nagy, J. A., Benjamin, L., Zeng, H., Dvorak, A. M., & Dvorak, H. F. (2008) · Angiogenesis · doi:10.1007/s10456-008-9099-z · Cited by 628 · cited 1×
“They have an important role in the transport of macromolecules across venules in the vascular hyperpermeability induced by VEGF-A, histamine, etc. (Dvorak et al, 1996; Nagy et al, 2008).”
BackgroundSelf-citationVascular endothelial growth factor C induces angiogenesis in vivo
Cao, Y., Linden, P., Farnebo, J., Cao, R., Eriksson, A., Kumar, V., Qi, J.-H., Claesson-Welsh, L., & Alitalo, K. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.24.14389 · Cited by 565 · cited 1×
“However, similar MV-like blood vessels are also induced by polymers containing VEGF-A164 or basic fibroblast growth factor (Cao et al, 1998) and by tumours expressing VEGF-A or basic fibroblast growth factor and plateletderived growth factor-BB (Paku and Paweletz, 1991; Bjorndahl et al, 2005; Nagy…”
BackgroundOzawa, C. R., Banfi, A., Glazer, N. L., Thurston, G., Springer, M. L., Kraft, P. E., McDonald, D. M., & Blau, H. M. (2004) · Journal of Clinical Investigation · doi:10.1172/jci18420 · Cited by 520 · cited 10×
“One mechanism by which MVs evolve into capillaries involves intraluminal bridging, a process that was originally discovered in tumour vessels (Nagy et al, 1995), but which has since been found to occur in the angiogenesis induced by Ad-VEGF-A164 (Pettersson et al, 2000) and healing wounds (Ren et al, 2002), and after…”
BackgroundInfluentialBlood vessels and nerves: common signals, pathways and diseases
Carmeliet, P. (2003) · Nature Reviews Genetics · doi:10.1038/nrg1158 · Cited by 516 · cited 2×
“…their inhibitory effects on angiogenesis do not cause excessive toxicity; it has become apparent in recent years that normal blood vessels, and also the central nervous system, require VEGF-A for maintenance and are compromised when circulating VEGF-A falls below threshold levels (Carmeliet, 2003).”
BackgroundVEGF-A and the Induction of Pathological Angiogenesis
Nagy, J. A., Dvorak, A. M., & Dvorak, H. F. (2007) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev.pathol.2.010506.134925 · Cited by 474 · cited 3×
“The other types of angiogenic vessels evolve from MVs and thus may be properly regarded as ‘daughter’ vessels (Figure 1) (Pettersson et al, 2000; Dvorak, 2003; Nagy et al, 2007).”
BackgroundSelf-citationIntermittent blood flow in a murine tumor: radiobiological effects.
Chaplin, D. J., Olive, P. L., & Durand, R. E. (1987) · PubMed · Cited by 436
Pettersson, A., Nagy, J. A., Brown, L. F., Sundberg, C., Morgan, E., Jungles, S., Carter, R., Krieger, J. E., Manseau, E. J., Harvey, V. S., et al. (2000) · Laboratory Investigation · doi:10.1038/labinvest.3780013 · Cited by 417 · cited 15×
“One mechanism by which MVs evolve into capillaries involves intraluminal bridging, a process that was originally discovered in tumour vessels (Nagy et al, 1995), but which has since been found to occur in the angiogenesis induced by Ad-VEGF-A164 (Pettersson et al, 2000) and healing wounds (Ren et al, 2002), and after…”
BackgroundInfluentialSelf-citationPathology of the Skin with Clinical Correlations
McKee, P. H. (1991) · Plastic and Reconstructive Surgery · doi:10.1097/00006534-199102000-00027 · Cited by 307
Nissen, L. J., Cao, R., Hedlund, E.-M., Wang, Z., Zhao, X., Wetterskog, D., Funa, K., Bråkenhielm, E., & Cao, Y. (2007) · Journal of Clinical Investigation · doi:10.1172/jci32479 · Cited by 290 · cited 1×
“…are also induced by polymers containing VEGF-A164 or basic fibroblast growth factor (Cao et al, 1998) and by tumours expressing VEGF-A or basic fibroblast growth factor and plateletderived growth factor-BB (Paku and Paweletz, 1991; Bjorndahl et al, 2005; Nagy et al, 2007; Nissen et al, 2007).”
BackgroundDvorak, A. M., Kohn, S., Morgan, E. S., Fox, P., Nagy, J. A., & Dvorak, H. F. (1996) · Journal of Leukocyte Biology · doi:10.1002/jlb.59.1.100 · Cited by 270 · cited 1×
“Not all open vessels are perfused continuously, and, over a few minutes, blood flow may follow different paths and even proceed in alternating directions through the same vessel (Chaplin et al, 1987).”
BackgroundSelf-citationGrunstein, J., Masbad, J. J., Hickey, R., Giordano, F., & Johnson, R. S. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.19.7282-7291.2000 · Cited by 255 · cited 2×
“Similarly, tumour cells expressing only VEGF-A120 form small tumours with numerous, large peripheral blood vessels (presumably MV), but with few, small intratumour vessels (Grunstein et al, 2000; Tozer et al, 2008).”
BackgroundFirst steps of tumor-related angiogenesis.
Paku, S., & Paweletz, N. (1991) · PubMed · Cited by 238
Unorthodox angiogenesis in skeletal muscle
Egginton, S. (2001) · Cardiovascular Research · doi:10.1016/s0008-6363(00)00282-0 · Cited by 233 · cited 1×
“…bridging, a process that was originally discovered in tumour vessels (Nagy et al, 1995), but which has since been found to occur in the angiogenesis induced by Ad-VEGF-A164 (Pettersson et al, 2000) and healing wounds (Ren et al, 2002), and after chronic vascular dilatation (Egginton et al, 2001).”
BackgroundHow Tumors Make Bad Blood Vessels and Stroma
Dvorak, H. F. (2003) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64309-x · Cited by 230 · cited 3×
“The other types of angiogenic vessels evolve from MVs and thus may be properly regarded as ‘daughter’ vessels (Figure 1) (Pettersson et al, 2000; Dvorak, 2003; Nagy et al, 2007).”
BackgroundSelf-citationSundberg, C., Nagy, J. A., Brown, L. F., Feng, D., Eckelhoefer, I. A., Manseau, E. J., Dvorak, A. M., & Dvorak, H. F. (2001) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64062-x · Cited by 212
Self-citation(2020) · CRC Press eBooks · doi:10.1201/9780429283024 · Cited by 202
Vascular Endothelial Growth Factor-A Promotes Peritumoral Lymphangiogenesis and Lymphatic Metastasis
Björndahl, M. A., Cao, R., Burton, J. B., Brakenhielm, E., Religa, P., Galter, D., Wu, L., & Cao, Y. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-2345 · Cited by 178 · cited 1×
“…are also induced by polymers containing VEGF-A164 or basic fibroblast growth factor (Cao et al, 1998) and by tumours expressing VEGF-A or basic fibroblast growth factor and plateletderived growth factor-BB (Paku and Paweletz, 1991; Bjorndahl et al, 2005; Nagy et al, 2007; Nissen et al, 2007).”
BackgroundMorphological Characteristics of the Microvasculature in Healing Myocardial Infarcts
Ren, G., Michael, L. H., Entman, M. L., & Frangogiannis, N. G. (2002) · Journal of Histochemistry & Cytochemistry · doi:10.1177/002215540205000108 · Cited by 165 · cited 1×
“…bridging, a process that was originally discovered in tumour vessels (Nagy et al, 1995), but which has since been found to occur in the angiogenesis induced by Ad-VEGF-A164 (Pettersson et al, 2000) and healing wounds (Ren et al, 2002), and after chronic vascular dilatation (Egginton et al, 2001).”
BackgroundNagy, J. A., Morgan, E. S., Herzberg, K. T., Manseau, E. J., Dvořàk, A. M., & Dvorak, H. F. (1995) · PubMed · Cited by 163
Self-citationVascular endothelial growth factor: Basic biology and clinical implications
Ferrara, N., & Keyt, B. (1997) · Experientia Supplementum · doi:10.1007/978-3-0348-9006-9_9 · Cited by 124 · cited 2×
“However, several VEGF-A isoforms differ strikingly in their capacities to bind heparin, and cell surface and matrix heparans (Ferrara and Keyt, 1997).”
BackgroundHartnett, M. E., Martiniuk, D., Byfield, G. E., Geisen, P., Zeng, G., & Bautch, V. L. (2008) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.08-1780 · Cited by 110 · cited 1×
“Also, in a model of retinal prematurity, an increased VEGF-A caused endothelial cleavage planes to orient laterally, rather than longitudinally, leading to the formation of enlarged vessels (Hartnett et al, 2008).”
BackgroundTozer, G. M., Akerman, S., Cross, N. A., Barber, P. R., Björndahl, M. A., Greco, O., Harris, S., Hill, S. A., Honess, D. J., Ireson, C. R., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-2011 · Cited by 106 · cited 2×
“Similarly, tumour cells expressing only VEGF-A120 form small tumours with numerous, large peripheral blood vessels (presumably MV), but with few, small intratumour vessels (Grunstein et al, 2000; Tozer et al, 2008).”
BackgroundStraume, O., Chappuis, P. O., Salvesen, H. B., HALVORSEN, O. J., Haukaas, S. A., Goffin, J. R., Bégin, L. R., Foulkes, W. D., & Akslen, L. A. (2002) · PubMed · Cited by 101
Pathology of the Skin With Clinical Correlations
Sandstrom, R. E. (1990) · Archives of Dermatology · doi:10.1001/archderm.1990.01670280139042 · Cited by 85 · cited 1×
“Vessels of this description closely resemble the nonmalignant VMs that occur, for example, in the skin, brain, etc. (McKee, 1996).”
BackgroundMicrocirculation in Cancer Metastasis
Orr, F. W., Buchanan, M. R., & Weiss, L. (2024) · CRC Press eBooks · doi:10.1201/9781003574682 · Cited by 76
Distensibility of single capillaries and venules in the rat and frog mesentery.
Swayne, G. T. G., Smaje, L. H., & Bergel, D. H. (1989) · PubMed · Cited by 57
VEGF-A Angiogenesis Induces a Stable Neovasculature in Adult Murine Brain
Stiver, S. I., Tan, X., Brown, L. F., Hedley‐Whyte, E. T., & Dvorak, H. F. (2004) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/63.8.841 · Cited by 48 · cited 1×
“…induced by Ad-VEGF-A164 are largely independent of the tissue in which they arise; similar vessel types form with similar kinetics in a wide variety of normal mouse and rat tissues, including skin, subcutis, fat, skeletal and heart muscle, and brain (Pettersson et al, 2000; Stiver et al, 2004).”
BackgroundSelf-citationFu, Y., Nagy, J. A., Dvořàk, A. M., & Dvorak, H. F. (2008) · Humana Press eBooks · doi:10.1007/978-1-59745-184-0_12 · Cited by 18
Self-citationDvorak, H. F. (2007) · Cambridge University Press eBooks · doi:10.1017/cbo9780511546198.159 · Cited by 6 · cited 1×
“Tumour angiogenesis is a relatively crude process that results from the unbalanced secretion of a small subset of cytokines, particularly VEGF-A (Dvorak, 2003, 2007; Nagy et al, 2007).”
BackgroundSelf-citation
Cited by
VEGF in signaling and disease: beyond discovery and development
Apte, R. S., Chen, D. S., & Ferrara, N. (2019) · Cell · doi:10.1016/j.cell.2019.01.021 · Cited by 2,721
“Understanding VEGF Biology in Cancer VEGF secreted by tumor cells and surrounding stroma stimulates the proliferation and survival of endothelial cells, leading to the formation of new blood vessels, which may be structurally abnormal and leaky (Ferrara, 2010a, 2010b; Jain, 2003; Nagy et al., 2009).”
Cancer immunoediting and resistance to T cell-based immunotherapy
O’Donnell, J. S., Teng, M. W. L., & Smyth, M. J. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0142-8 · Cited by 1,759
Normalization of the Vasculature for Treatment of Cancer and Other Diseases
Goel, S., Duda, D. G., Xu, L., Munn, L. L., Boucher, Y., Fukumura, D., & Jain, R. K. (2011) · Physiological Reviews · doi:10.1152/physrev.00038.2010 · Cited by 1,605
Tumor targeting via EPR: Strategies to enhance patient responses
Golombek, S. K., May, J.-N., Theek, B., Appold, L., Drude, N., Kiessling, F., & Lammers, T. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.07.007 · Cited by 1,262
“Newly formed blood vessels typically occur in higher densities in tumor tissue [32,33], they often lack a smooth muscle layer and pericytes [34], they have a larger lumen and wider Golombek et al.”
BackgroundChallenges and strategies in anti-cancer nanomedicine development: An industry perspective
Hare, J. I., Lammers, T., Ashford, M. B., Puri, S., Storm, G., & Barry, S. T. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.04.025 · Cited by 1,214
Metadata
- Authors
- Nagy, J. A., Chang, S.-H., Dvorak, A. M., & Dvorak, H. F.
- Affiliations
- Beth Israel Deaconess Medical Center (US)
- Corresponding author
- Dvorak, H F
- ORCID
- Nagy, J A
- Venue
- British Journal of Cancer
- Published
- 2009-02-24
- Volume
- 100
- Issue
- 6
- Pages
- 865-869
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- PMC
- PMC2661770
- OpenAlex
- W2063556542
- Cited by
- 611
- References
- 38
- Citations by year
- 2026: 30 · 2025: 39 · 2024: 62 · 2023: 47 · 2022: 50 · 2021: 53 · 2020: 61 · 2019: 47 · 2018: 51 · 2017: 48 · 2016: 22 · 2015: 16 · 2014: 12 · 2013: 18 · 2012: 20
- FWCI
- 1.38
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-sa
- www.springer.com/tdm (unspecified)
- Locations
- British Journal of Cancer (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- National Foundation for Cancer Research
- National Heart, Lung, and Blood Institute (R01HL064402, HL-64402)
- National Cancer Institute (P01 CA 92644, P01CA092644)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Health Sciences › Medicine › Oncology › Lymphatic System and Diseases
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Keywords
- tumor vasculature, VEGF-A, anti-VEGF therapy, tumor angiogenesis, anti-angiogenic therapy resistance
- MeSH terms
- Animals, Blood Vessels, Capillaries, Humans, Neoplasms, Neovascularization, Pathologic, Vascular Endothelial Growth Factor A
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.